Spaccavento Felice Antonio, De Virgilio Suglia Cesare, Tafuri Silvio, De Trizio Angela, Giannuzzi Rossella, Cavallera Filomena, Turco Fabio
Palliative Care Unit, ASL Bari (Bari Local Health Trust), Bari, Italy.
Department of Precision and Regenerative Medicine and Ionian Area (DiMePreJ), University of Bari Aldo Moro, Bari, Italy.
J Cannabis Res. 2025 Aug 8;7(1):55. doi: 10.1186/s42238-025-00303-w.
Control of pain in patients affected by chronic pancreatitis with recurrent exacerbations is a challenging condition, with conventional therapies often providing limited relief. This case report describes the use of medical cannabis as a novel approach in a patient with refractory chronic pancreatitis, contributing to the growing interest in alternative treatments for pain and inflammation in similar complex cases.
A 54-year-old woman with a 24-year history of chronic pancreatitis caused by recurrent acute pancreatitis presented with persistent, severe abdominal pain and recurrent exacerbations despite undergoing numerous conventional interventions, including cholecystectomy, enzyme supplementation, repeated endoscopic retrograde cholangiopancreatographies (ERCPs), and stent placements. Imaging and laboratory findings confirmed chronic pancreatitis, with evidence of Oddi sphincter stenosis and microlithiasis. The patient was initially managed with standard pain relief therapy, digestive enzymes, and endoscopic interventions, all of which failed to provide lasting relief. In February 2024, she began treatment with a medical cannabis formulation rich in Cannabidiol, under the supervision of her healthcare provider. This intervention led to substantial pain reduction, cessation of acute episodes, improved appetite, and enhanced quality of life.
This case illustrates that medical cannabis may offer a promising alternative for managing chronic pancreatitis, especially when conventional treatments prove ineffective. This outcome underscores the need for further research on cannabinoids as a therapeutic option in chronic pain and inflammation management for pancreatitis and other challenging conditions.
对于患有复发性加重的慢性胰腺炎患者的疼痛控制是一项具有挑战性的情况,传统疗法往往只能提供有限的缓解。本病例报告描述了医用大麻在一名难治性慢性胰腺炎患者中的新应用,这也引发了人们对类似复杂病例中疼痛和炎症替代治疗方法的更多关注。
一名54岁女性,有24年复发性急性胰腺炎导致的慢性胰腺炎病史,尽管接受了包括胆囊切除术、补充酶、多次内镜逆行胰胆管造影(ERCP)和放置支架在内的多种传统干预措施,但仍出现持续的严重腹痛和反复加重。影像学和实验室检查结果证实为慢性胰腺炎,伴有奥狄括约肌狭窄和微结石症。患者最初接受标准的疼痛缓解治疗、消化酶治疗和内镜干预,但均未能提供持久缓解。2024年2月,在其医疗服务提供者的监督下,她开始使用富含大麻二酚的医用大麻制剂进行治疗。这一干预措施使疼痛大幅减轻,急性发作停止,食欲改善,生活质量提高。
本病例表明,医用大麻可能为慢性胰腺炎的管理提供一种有前景的替代方法,特别是在传统治疗无效时。这一结果强调了有必要进一步研究大麻素作为胰腺炎和其他具有挑战性疾病慢性疼痛和炎症管理的治疗选择。